BlackRock Investment Management’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

BlackRock Investment Management’s Portfolio CADX Stock Details CADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-169,299	Closed	-$1.53M	–	3486
2013 Q4	$1.53M	Sell	169,299 -5,831	-3%	-$42.1K	﹤0.01%	2203
2013 Q3	$1.1M	Buy	175,130 +10,381	+6%	+$66K	﹤0.01%	2372
2013 Q2	$1.12M	Buy	+164,749	New	+$1.15M	﹤0.01%	2272

Other funds holding CADX

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

BlackRock Investment Management's CADX Position: Q1 2014 in Review

BlackRock Investment Management sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 169,299 shares — an estimated $1.53M sold.

BlackRock Investment Management first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $1.53M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

BlackRock Investment Management reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
BlackRock Investment Management sold 169,299 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $1.53M.
BlackRock Investment Management first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
BlackRock Investment Management's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $1.53M in Q4 2013.
3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on BlackRock Investment Management's 13F filing for Q1 2014, filed 2 May 2014.